C4x Discovery Signs Exclusive Global Licence Worth Up To $402 Million With Astrazeneca

Nov 28, 202207:42 UTC

AstraZeneca PLC AZN:

SIGNS EXCLUSIVE GLOBAL LICENCE WORTH UP TO $402 MILLION WITH ASTRAZENECA FOR DEVELOPMENT & COMMERCIALISATION OF NRF2 ACTIVATOR PROGRAMME
C4XD WILL RECEIVE PRE-CLINICAL MILESTONE PAYMENTS WORTH UP TO $16 MILLION AHEAD OF FIRST CLINICAL TRIAL
IN ADDITION, C4XD IS ELIGIBLE TO RECEIVE A FURTHER POTENTIAL $385.8 MILLION